Changing prevalence of asthma in Australian children.

Department of Medicine, University of Sydney, NSW, Australia.
BMJ Clinical Research (Impact Factor: 14.09). 07/1994; 308(6944):1591-6. DOI: 10.1136/bmj.308.6944.1591
Source: PubMed

ABSTRACT To investigate whether prevalence of asthma in children increased in 10 years.
Serial cross sectional studies of two populations of children by means of standard protocol.
Two towns in New South Wales: Belmont (coastal and humid) and Wagga Wagga (inland and dry).
Children aged 8-10 years: 718 in Belmont and 769 in Wagga Wagga in 1982; 873 in Belmont and 795 in Wagga Wagga in 1992.
History of respiratory illness recorded by parents in self administered questionnaire; airway hyperresponsiveness by histamine inhalation test; atopy by skin prick tests; counts of house dust mites in domestic dust.
Prevalence of wheeze in previous 12 months increased in Belmont, from 10.4% (75/718) in 1982 to 27.6% (240/873) in 1992 (P < 0.001), and in Wagga Wagga, from 15.5% (119/769) to 23.1% (183/795) (P < 0.001). The prevalence of airway hyperresponsiveness increased twofold in Belmont to 19.8% (173/873) (P < 0.001) and 1.4-fold in Wagga Wagga to 18.1% (P < 0.05). The prevalence of airway hyperresponsiveness increased mainly in atopic children only, but the prevalence of atopy was unchanged (about 28.5% in Belmont and about 32.5% in Wagga Wagga). Numbers of house dust mites increased 5.5-fold in Belmont and 4.5-fold in Wagga Wagga.
We suggest that exposure to higher allergen levels has increased airway abnormalities in atopic children or that mechanisms that protected airways of earlier generations of children have been altered by new environmental factors.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The immune system is exquisitely sensitive to environmental changes. Diet constitutes one of the major environmental factors that exerts a profound effect on immune system development and function. Epigenetics is the study of mitotically heritable, yet potentially reversible, molecular modifications to DNA and chromatin without alteration to the underlying DNA sequence. Nutriepigenomics is an emerging discipline examining the role of dietary influences on gene expression. There is increasing evidence that the epigenetic mechanisms that regulate gene expression during immune differentiation are directly affected by dietary factors or indirectly through modifications in gut microbiota induced by different dietary habits. Short-chain fatty acids, in particular butyrate, produced by selected bacteria stains within gut microbiota, are crucial players in this network.
    Nutrients 11/2014; 6(11):4706-4719. DOI:10.3390/nu6114706 · 3.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background. The CD14 gene has an important role in the detection of inflammatory provoking pathogens and in the ensuing signaling of the innate immune response. We assessed the role of CD14 C-159T, G-1359T in the expression of asthma, croup, and allergy in Canadian school children of ages 6 to 14 years. Methods. Children attending schools in a rural community participated in a cross-sectional survey of respiratory health. Following consent, we conducted clinical assessments to collect buccal swabs for genotyping and perform skin prick testing (SPT) to determine atopic status. Genotyping and SPT results were available for 533 and 499 children, respectively. Separate multivariable analyses that included both polymorphisms were conducted for each phenotype. Results. The prevalence of asthma, allergy, and croup was 18.6%, 22.4%, and 6.6%, respectively. Children with the T/T variant of CD14 G-1359T were more likely to have physician diagnosed asthma (26.8%). Children with C/C variant of CD14 C-159T had a significantly lower prevalence of croup (2.6%). Haplotype analyses of the two CD14 polymorphisms showed that individuals with the T|T haplotype combination were significantly more likely to have asthma (P = 0.014). Conclusions. In this study, CD14 variants are important for the expression of croup and asthma but not atopy.
    Disease markers 11/2013; 35(6):765-771. DOI:10.1155/2013/434920 · 2.17 Impact Factor
    This article is viewable in ResearchGate's enriched format
  • [Show abstract] [Hide abstract]
    ABSTRACT: Asthma is a chronic inflammatory disease of the airways characterised by circadian and episodic symptoms, including wheezing, breathlessness, chest tightness and/or cough. It is one of the most common chronic diseases in adults and children, affecting approximately 15 million people in the US alone. Asthma is associated with considerable direct costs (e.g. hospitalisation, emergency care and drug therapy) and indirect costs (e.g. loss of income, loss of school days and premature death). Patient education and objective parameters of assessment are important aspects of asthma management. With the recognition of the need to reduce the underlying airways inflammation, the regular use of anti-inflammatory drugs [e.g. inhaled corticosteroids, nedocromil or sodium cromoglycate (cromolyn sodium)] is currently recommended for prophylaxis of asthma. Inhaled short-acting bronchodilators are used intermittently for relief of acute asthma symptoms. Salmeterol is a long-acting inhaled β2-agonist that produces significant bronchodilation and protects against asthma induced by a number of bronchoconstricting stimuli (including exercise) for at least 12 hours. In clinical trials of up to 12 months’ duration in patients with mild to moderate asthma, inhaled salmeterol 50µg twice daily was more effective than short-acting inhaled β2-agonists [salbutamol (albuterol) and terbutaline] in improving lung function, alleviating symptoms and reducing the requirement for additional inhaled salbutamol Salmeterol was at least as effective as sustained-release theophylline in controlling nocturnal asthma symptoms. Recent studies have shown that addition of salmeterol to existing low dosage inhaled corticosteroid therapy is more beneficial than increasing the dosage of inhaled corticosteroids in patients with inadequate control of asthma symptoms. Salmeterol has been well tolerated in clinical trials and there is no convincing evidence to suggest that long term use of salmeterol increases asthma morbidity or mortality. Regular use of long-acting β2-agonists such as salmeterol may result in some decreased protection against induced bronchoconstriction, but clinically significant tachyphylaxis to bronchodilatory response has not been demonstrated. It is important to emphasise that inhaled long-acting β2-agonists, including salmeterol, should be used in conjunction with, and not as a replacement for, oral or inhaled corticosteroids. Long-acting β2-agonists should always be used in conjunction with anti-inflammatory drugs (and short-acting β2-agonists for symptom relief). In conclusion, available data and recommendations from recent UK and US asthma guidelines suggest that inhaled salmeterol is effective in preventing exercise-induced asthma and, when added to low dose inhaled corticosteroids, is a useful alternative to increasing the inhaled corticosteroid dosage for long term control of symptoms (especially those occurring at night).
    Disease Management and Health Outcomes 01/1997; 2(1). DOI:10.2165/00115677-199702010-00004 · 0.36 Impact Factor

Full-text (2 Sources)

Available from
May 30, 2014